Record revenue masks margin miss; profitability lags despite 52% growth

Revenue grew 52.3% YoY (₹392.7 Cr); EBITDA ₹91.7 Cr at 23.3% margin; PAT grew only 8% YoY despite revenue surge

₹106.7 Cr out of ₹392.7 Cr = 27.2% of total revenue

Specific operational milestones claimed but EBITDA margins still only 4-5% at breakeven; limited to incremental margin expansion near-term

Delivered ARPOB data shows Noida Extension and Model Town (New Delhi) both exceeded ₹50,000 ARPOB

Q1 consolidated EBITDA margin came at 23.3%, below 24-25% guidance band; management reiterated 'upwards of 24%' but already facing margin pressure

PAT growth of only 8% YoY despite 52% revenue growth; NPM compressed to 11.4%; depreciation ₹29 Cr/quarter and interest ₹6.6 Cr offsetting operational leverage

Prior guidance was 3 years; management now confident to achieve in 2.5 years. 3,200 beds already announced/under construction; remaining 1,800 beds to follow. Acquisition playbook validating faster ramp-up.

Reiterated 'upwards of 24% EBITDA margin for full FY27', but Q1 delivered 23.3%. No formal cut; management defending guidance despite near-term pressure from new hospital drag and capex absorption.

Faridabad Sector 20 reached breakeven in 9 months vs 12-14 months expected; Agra at 20-23% EBITDA margin (vs 11% starting baseline). Management now guiding newer hospitals to 25-27% EBITDA margins within 2 years (by FY28-29).

Explicitly restricting government mix in new hospitals to ₹50k ARPOB vs prior ₹35-40k. International expansion initiatives underway (5 OPD centers opening in CIS/Africa).

Capex per bed increased from ₹30.7 Lakh (historical) to ₹61.4 Lakh (recent). Guidance for next 1,800 beds: ₹75-80 Lakh per bed (vs ₹61.4 Lakh now). Driver: land price inflation, equipment (oncology LINAC), scale/brand positioning in NCR.

3,200 beds already announced (Gurugram + brownfield). 5,000 achievable earlier than 3-year timeline, likely ~2.5 years. Focus remains North Delhi-NCR, with exploration of UP capital cities and Rajasthan/Haryana metros. All new hospitals targeting ₹50k ARPOB.

New hospitals already 90%+ cash/insurance; government mix intentionally restricted. 5 OPD centers opening in CIS/Africa; senior marketing person posted to Africa. No quantified benefit given; claimed 'playbook evident' but did not provide revenue/margin impact.

Occupancy not stagnant; census beds increased so percentage appears lower. Delhi census rose 100→150 beds; Faridabad 100→200 beds. IPD volumes and revenue growing QoQ. Empanelment mostly complete but intentionally restricting government business. On track for breakeven in 15-17 months (Delhi) and holding 9-month (Faridabad).

High capex (Gurgaum, oncology LINAC orders) and bank debt increase (₹210→₹300 Cr) driving depreciation ₹29 Cr/quarter and interest ₹6.6 Cr/quarter. This is temporary; high capex not planned for upcoming quarters. Pressure will ease. EBITDA margin guidance 24-25% maintained.

Never. No guidance for 28% EBITDA at group level. Company will continue adding new hospitals; once Delhi/Faridabad contribute, Gurugram will ramp. Targeting 'upwards of 24%' EBITDA margins at group level FY27, with 'a percentage up or so in few years' but no 28% target.

ALOS decline due to surgical mix in new hospitals and low government % in those units (government patients have higher ALOS). Government mix rose 4pp to 40%, but volumes declining; increase is 1-2% from CGHS rate revision only. Should stabilize at current ALOS level.

No comment yet; waiting for regulatory frameworks. Historically, government has supported private hospital growth (stent capping, implant capping happened but industry adapted). If cost optimization needed, hospitals will do it. Long way from any implementation.

₹20-30 Cr per quarter (₹29 Cr this quarter). Same trend for Q2-Q4 FY27 because Gurugram won't be operational until Q1 FY28. Fixed assets ₹1,200 Cr implied from ₹20-30 Cr quarterly depreciation.

Within two years (by FY28-29), new hospitals should reach 25-27% EBITDA margins, like mature units. Agra already at 20-23%, so recovery faster than 2 years for that asset. Confidence high based on recent quarter performance.

Greater Noida construction up and kicking; delayed slightly due to monsoon. Noida Extension final drawings under review. Full capacity expected in 15-18 months; 200 beds earlier, 250 beds in 18-19 months.

Q1 delivered 52.3% YoY, well ahead of 37%. Full year tracking 'on pace' for guidance; ramp from new hospitals (Gurugram starting Q1 FY28) will sustain momentum.

Q1 delivered 23.3%, below 24-25% band. Management reiterated 'upwards of 24%' but acknowledged new hospital drag. Older hospitals at 28.1% adjusted EBITDA show mature-unit leverage; new hospitals will grow into 24-25% EBITDA by full year as volumes ramp.

Agra already at 20-23%; Faridabad Sector 20 at breakeven with path to 15-20% within 15-18 months. Delhi Model Town on track. Assumes occupancy ramp to 70%+ and surgical mix shift in newer units. Risk: if government mix expands or competitive pricing pressure emerges.

Prior capex per bed was ₹30.7 Lakh; recent ₹61.4 Lakh reflects land inflation, equipment (LINAC ~₹15-20 Cr per unit), brand positioning. Management reiterated 1,800 beds remains on plan to reach 5,000 total. Debt increased to ₹300 Cr to fund, with rest from internal accruals.

Q1 EBITDA margin 23.3% vs 24-25% guidance; PAT growth only 8% despite 52% revenue growth. Depreciation ₹29 Cr/quarter and interest ₹6.6 Cr/quarter eating into earnings. New hospital drag expected to persist 12-18 months before breakeven-to-ramp transition.

New hospitals (Delhi Model Town, Faridabad Sector 20) operating at low occupancy percentages (29% and 49%) due to census bed expansion rather than strong demand. Faridabad at breakeven with 4-5% EBITDA margin; occupancy recovery to 70%+ will take 12-18 months per management guidance. Delay in occupancy ramp would extend breakeven timeline.

Debt increased from ₹210 Cr to ₹300 Cr (43% increase) for Gurgaon acquisition. Management states comfort up to 2x trailing EBITDA (~₹180-190 Cr based on EBITDA ₹91.7 Cr/quarter), implying current leverage above comfort zone. If EBITDA growth stalls or interest rates rise, debt service burden will increase further, limiting capex flexibility.

Panel recommendation on capping hospital room charges to 3-star hotel rates could impact ARPOB, especially in older hospitals with higher government mix (40% of revenue). New hospitals insulated (9-10% government mix), but older Noida/Jhansi units vulnerable. Management downplayed risk citing historical precedent (stent, implant capping), but regulatory environment remains uncertain.

Capex per bed increased from ₹30.7 Lakh (historical) to ₹61.4 Lakh (recent) to ₹75-80 Lakh (guidance for next 1,800 beds). Gurugram at ~₹1 Cr per bed—well above guidance. Land inflation, equipment, and brand positioning driving costs higher. If trend continues, 1,800-bed capex could exceed current assumptions by ₹500-1,000 Cr.